Beacon Pointe Advisors’s Aquestive Therapeutics AQST Stock Holding History

Beacon Pointe Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$251K	Buy	+60,500	New	+$246K	﹤0.01%	1632
2025 Q3	–	Sell	-60,000	Closed	-$199K	–	1386
2025 Q2	$199K	Hold	60,000	–	–	﹤0.01%	1192
2025 Q1	$174K	Hold	60,000	–	–	﹤0.01%	1164
2024 Q4	$214K	Hold	60,000	–	–	﹤0.01%	1127
2024 Q3	$299K	Hold	60,000	–	–	﹤0.01%	1024
2024 Q2	$156K	Hold	60,000	–	–	﹤0.01%	1205
2024 Q1	$256K	Hold	60,000	–	–	﹤0.01%	1162
2023 Q4	$121K	Hold	60,000	–	–	﹤0.01%	1266
2023 Q3	$91.8K	Hold	60,000	–	–	﹤0.01%	1288
2023 Q2	$99K	Buy	+60,000	New	+$109K	﹤0.01%	1050
2023 Q1	–	Sell	-60,000	Closed	-$54.1K	–	1143
2022 Q4	$54.1K	Hold	60,000	–	–	﹤0.01%	1039
2022 Q3	$70K	Hold	60,000	–	–	﹤0.01%	972
2022 Q2	$38K	Buy	+60,000	New	+$79.8K	﹤0.01%	1028

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Beacon Pointe Advisors's AQST Position: Q1 2026 in Review

Beacon Pointe Advisors opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 60,500 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #1632 among its holdings. This is a return to the name: Beacon Pointe Advisors previously reported a position in AQST as recently as Q2 2025.

Beacon Pointe Advisors first reported a position in AQST in Q2 2022 and has held it in 13 quarters since. The position peaked at $299K in Q3 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Beacon Pointe Advisors held 60,500 shares of Aquestive Therapeutics worth $251K as of Q1 2026.
Aquestive Therapeutics was a new Beacon Pointe Advisors position in Q1 2026.
Aquestive Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1632 holding.
Beacon Pointe Advisors first reported a position in Aquestive Therapeutics in Q2 2022 and has held it in 13 quarters since.
Beacon Pointe Advisors's Aquestive Therapeutics position peaked at $299K in Q3 2024.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.